Iwamoto, Takayuki
Niikura, Naoki
Ogiya, Rin
Yasojima, Hiroyuki
Watanabe, Ken-ichi
Kanbayashi, Chizuko
Tsuneizumi, Michiko
Matsui, Akira
Fujisawa, Tomomi
Iwasa, Tsutomu
Shien, Tadahiko http://orcid.org/0000-0003-3202-5512
Saji, Shigehira
Masuda, Norikazu
Iwata, Hiroji
Article History
Received: 9 May 2019
Accepted: 6 September 2019
First Online: 16 September 2019
Competing Interests
: S.S: Grants and personal fees from Eisai, Chugai, Astra Zeneca, Takeda, Novartis Nihon Kayaku and Taiho. Personal fees from Kyowahakko Kirin, Pfizer, Daiichi Sankyo. Grants from Ono, outside the submitted work. NM: Honoraria from Chugai, AstraZeneca, Pfizer, Eli-Lilly, Eisai and Takeda. Research funding from Chugai, AstraZeneca, Kyowa-Kirin, MSD, Novartis, Pfizer, Eli-Lilly, Eisai and Daiichi Sankyo. Board of directors: Japan Breast Cancer Research Group Association. Relevant financial activities outside the submitted work. The other authors declare that they have no competing interests.